Promoter holding
64.27%
CL
Claris Limited - Due diligence report
A 360° intelligence report on Claris Injectables: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Claris Injectables — 360° Intelligence Report
Generated from MCA filings & public records69/100
Trust Score
Moderate
Claris Injectables is assessed as Moderate with a Trust Score of 69/100. Claris Injectables is an active public limited indian non-government company incorporated in 2013, operating in the Business Services sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Claris Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
Charges position: 2 open (153.00 cr) · 14 satisfied (1,126.42 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 10 | 48.0 cr |
| Idbi Trusteeship Services Limited | 3 | 48.0 cr |
| Ecl Finance Limited | 1 | 48.0 cr |
| Indian Overseas Bank | 2 | 48.0 cr |
Compliance Score: 66/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (92 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARJUN SUSHILKUMAR HANDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ROOPESH MADAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Hardik Pankajkumar Dagli | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| K H KANJARIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MILINA PURNENDU BOSE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHYAMSUNDER KASHIRAM SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMIT SURESHKUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Hardik Pankajkumar Dagli | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ashu Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
6
Group entities
6
Capital events
4 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Abellon Cleanenergy Ghana Limited | Subsidiary Company | 74.00% |
| Abellon Cleanenergy Limited | Subsidiary Company | 74.00% |
| Catalys Venture Cap Limited | Subsidiary Company | 74.00% |
| Claris Capital Limited | Subsidiary Company | 74.00% |
| Bhavnagar Biomass Power Projects Private Limited | Subsidiary Company | 74.00% |
| Abellon Co-gen Limited | Subsidiary Company | 74.00% |
| Abellon Goodsteps Limited | Subsidiary Company | 74.00% |
| Claris Lifesciences Colombia Limitada | Subsidiary Company | 74.00% |
| Claris Middle East Fz Llc | Subsidiary Company | 74.00% |
| Claris Sterione | Subsidiary Company | 74.00% |
Key managerial personnel: Hardik Pankajkumar Dagli (CFO) · SHYAMSUNDER KASHIRAM SHARMA (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.20 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 153.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view51/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events10 Nov 2025
Director appointed
Ashu Jain (Company Secretary)
31 Dec 2024
Director ceased
KIRITKUMAR HIMATLAL KANJARIA
15 Dec 2024
Last AGM held
Annual general meeting
13 Dec 2024
Director ceased
ROOPESH MADAN
27 Nov 2024
Director appointed
AMIT SURESHKUMAR SHARMA (Additional Director)
11 Oct 2024
Director appointed
Hardik Pankajkumar Dagli (Cfo)
08 Oct 2024
Director appointed
Hardik Pankajkumar Dagli (CFO)
03 Oct 2024
Charge satisfied
Others
31 Mar 2024
Latest balance sheet
Filed with ROC
11 Jan 2024
Director appointed
ROOPESH MADAN (Director)
26 Sep 2023
Charge created
Others - 150.00 cr
31 Aug 2023
Charge satisfied
Others
19 Jun 2023
Charge satisfied
Indian Overseas Bank
15 May 2023
Charge satisfied
Others
07 Oct 2022
Charge created
Others - 16.80 cr
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 6 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Kcp Exports Private Limited | U51909DL2005PTC138357 | New Delhi, Delhi, India |
| Avp Crafts Private Limited | U36999RJ2020PTC072514 | Jaipur, Rajasthan, India |
| Furgonomics By Untitled Private Limited | U36100DL2021PTC388815 | Delhi, Delhi, India |
| Aman Ventures Private Limited | U52100HR2015PTC055829 | Gurgaon, Haryana, India |
| Bhavya Srishti Udyog Private Limited | U27320CT2019PTC009813 | Bemetara, Chattisgarh, India |
| D.A.V. Containers Private Limited | U21023HR2008PTC038088 | Ladwa, Haryana, India |
| Kuche7 Manufacturing Private Limited | U36999MH2019PTC327994 | Mumbai, Maharashtra, India |
| Nec Packaging Limited | U21029PB1995PLC016532 | Punjab, Punjab, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Claris Injectables before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Claris Injectables: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Claris Injectables - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Claris Injectables pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Claris Injectables - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Claris Injectables an active company?
Claris Injectables has MCA status “Active” with a compliance score of 66/100 (Moderate).
Is Claris Injectables financially healthy?
Claris Injectables has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.
Should I do business with Claris Injectables?
Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Claris Injectables?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 9 active director(s) are on record.
Does Claris Injectables have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 14 earlier charge(s) stand satisfied.
Is Claris Injectables up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 66/100 (Moderate).
Is it risky to lend to Claris Injectables?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
